(Q38078400)

28 August 2017

1 reference

title

Monoclonal antibodies therapies for ovarian cancer (English)

1 reference

28 August 2017

1 reference

1 reference

Ilary Ruscito

3

0 references

Maria Luisa Gasparri

object named as

Maria Luisa Gasparri

4

0 references

Filippo Bellati

object named as

Filippo Bellati

2

0 references

Simone Ferrero

7

object named as

Simone Ferrero

1 reference

28 August 2017

Umberto Leone Roberti Maggiore

1

1 reference

28 August 2017

Franco Alessandri

5

1 reference

28 August 2017

Pier Luigi Venturini

6

1 reference

28 August 2017

language of work or name

English

0 references

publication date

4 February 2013

1 reference

Expert Opinion on Biological Therapy

28 August 2017

1 reference

28 August 2017

13

1 reference

28 August 2017

5

1 reference

28 August 2017

739-764

1 reference

Ovarian cancer: etiology, risk factors, and epidemiology

28 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

New drugs for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Immunotherapies in rheumatologic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Immunotherapies in dermatologic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Immunotherapy in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Immunotherapy in renal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Immunotherapy in miscellaneous medical disorders Graves ophthalmopathy, asthma, and regional painful syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Monoclonal antibodies in gynecological cancer: a critical point of view

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Catumaxomab: clinical development and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Tolerability and safety of rituximab (MabThera).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Use of monoclonal antibodies in the treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Induction of angiogenesis during the transition from hyperplasia to neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Bevacizumab in endometrial cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Incorporation of bevacizumab in the primary treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Implications of EGFR inhibition in ovarian cancer cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Immune effects of trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Abagovomab for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

A monoclonal antiidiotypic antibody ACA 125 mimicking the tumor-associated antigen CA 125 for immunotherapy of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Immunotherapy of human ovarian carcinoma with OvaRex MAb-B43.13 in a human-PBL-SCID/BG mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

A step further in understanding the biology of the folate receptor in ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Overexpression of folate binding protein in ovarian cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Folate receptor alpha as a tumor target in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Farletuzumab in epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

CD28/B7 system of T cell costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

21 January 2018

The B7 family revisited

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

The interaction properties of costimulatory molecules revisited.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Biomarkers in the development of anti-angiogenic therapies for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evalu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

The multifaceted circulating endothelial cell in cancer: towards marker and target identification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Antiangiogenic drugs in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Functional folate receptor alpha is elevated in the blood of ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Clinical translation of folate receptor-targeted therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer S

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Ovarian cancer, version 3.2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: Effect of the radionuclide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.767328

10.1517/14712598.2013.767328

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference